Diagnos (TSE:ADK)
:ADK
Top Page
Diagnos
(ADK)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.26
▼(-26.94% Downside)
Action:ReiteratedDate:03/02/26
The score is primarily held down by weak financial performance—declining TTM revenue, deeply negative profitability, and persistent cash burn that increases funding risk. Technical indicators are broadly neutral but with negative MACD and price below key mid-term averages, offering limited support. Valuation is also constrained by a negative P/E and no dividend yield data.
Positive Factors
Improving equity position
Recent movement to positive equity provides a cleaner balance sheet base and reduces immediate insolvency risk. That repair increases capacity to absorb losses, improves lender/investor confidence, and creates a modest cushion that supports survival and strategic options over the next 2–6 months.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow indicates ongoing cash consumption that will require financing or dilution. Persistent burn constrains investment in product and sales, increases refinancing risk within months, and limits the company’s ability to execute strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving equity position
Recent movement to positive equity provides a cleaner balance sheet base and reduces immediate insolvency risk. That repair increases capacity to absorb losses, improves lender/investor confidence, and creates a modest cushion that supports survival and strategic options over the next 2–6 months.
Read all positive factors
Diagnos (ADK) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$33.11M
Dividend YieldN/A
Average Volume (3M)342.67K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth-48.53%
EPS Growth-9.66%
CountryCA
Employees16
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.01
Shares Outstanding120,412,550
10 Day Avg. Volume531,548
30 Day Avg. Volume342,665
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)-6.56
Price to Sales (P/S)117.69
P/FCF Ratio-9.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Diagnos Business Overview & Revenue Model
Company Description
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software too...
How the Company Makes Money
null...
Diagnos Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 68.16K | 103.80K | 170.16K | 438.83K | 267.07K | 331.52K |
| Gross Profit | -1.43M | -943.56K | 35.80K | -418.30K | -347.53K | -473.45K |
| EBITDA | -4.10M | -3.56M | -2.45M | -2.10M | -2.45M | -1.93M |
| Net Income | -4.71M | -4.29M | -3.12M | -2.61M | -2.05M | -3.38M |
Balance Sheet | ||||||
| Total Assets | 3.90M | 3.64M | 663.79K | 1.54M | 1.95M | 2.43M |
| Cash, Cash Equivalents and Short-Term Investments | 3.40M | 3.24M | 219.01K | 920.91K | 1.36M | 1.87M |
| Total Debt | 2.00M | 3.07M | 3.19M | 1.19M | 471.68K | 337.55K |
| Total Liabilities | 2.41M | 3.40M | 3.72M | 1.66M | 818.19K | 614.78K |
| Stockholders Equity | 1.50M | 233.11K | -3.05M | -113.51K | 1.13M | 1.82M |
Cash Flow | ||||||
| Free Cash Flow | -3.79M | -3.65M | -2.16M | -2.07M | -1.40M | -2.66M |
| Operating Cash Flow | -3.78M | -3.64M | -2.15M | -2.04M | -1.36M | -2.64M |
| Investing Cash Flow | -260.32K | -3.11M | -14.02K | 503.52K | 262.93K | -759.98K |
| Financing Cash Flow | 4.37M | 6.62M | 2.08M | 1.60M | 882.82K | 3.83M |
Diagnos Technical Analysis
Negative
0.36
Price Trends
0.29
Negative
0.31
Negative
0.29
Negative
Market Momentum
>-0.01
Positive
46.20
Neutral
57.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Negative. The current price of 0.36 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.29, and above the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 57.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ADK.
Diagnos Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | C$10.95M | -11.57 | ― | ― | 16.04% | -455.38% | |
48 Neutral | C$54.38M | -2.31 | -207.53% | ― | ― | 7.04% | |
45 Neutral | C$33.11M | -9.48 | 3086.87% | ― | -48.53% | -9.66% | |
42 Neutral | C$9.93M | -5.12 | 6239.15% | ― | ― | 48.94% | |
42 Neutral | C$6.60M | -4.68 | ― | ― | ― | 81.01% | |
| ― | C$11.43M | -21.40 | 527.45% | ― | ― | -67.11% |
* General Sector Average
TSE:ADK
Diagnos
0.28
>-0.01
-1.79%
TSE:AIDR
Rocket Doctor AI
0.60
0.13
27.66%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.69
0.29
72.50%
TSE:UDOC
UniDoc Health Corp
0.12
-0.21
-64.62%
TSE:NARA
PanGenomic Health, Inc. Class A
0.47
0.23
95.83%
TSE:DMED
DiagnaMed Holdings Corp.
0.09
0.07
260.00%
Diagnos Corporate Events
Business Operations and StrategyProduct-Related Announcements
Diagnos to Showcase AI Eye-Health Platform at Toronto Growth Investor Conference
Positive
Feb 24, 2026
Diagnos Inc., a Canadian AI-driven medical imaging specialist focused on early detection of eye-related and other critical health issues, leverages its FLAIRE platform and CARA retinal analysis tool to deliver cost-effective, real-time screening f...
Business Operations and Strategy
Diagnos Wins $1M-Plus Federal Backing for Next-Generation Retinal AI Research
Positive
Feb 4, 2026
Diagnos Inc. and Montreal-based engineering school École de technologie supérieure have secured more than C$1 million in federal funding, led by a five-year NSERC Alliance grant and additional Mitacs support, to accelerate development of...
Business Operations and Strategy
Diagnos Hires Investor Brand Network to Boost Market Visibility
Positive
Jan 15, 2026
Diagnos Inc. has engaged Investor Brand Network (IBN) to provide corporate communication and market awareness services in a one-year agreement starting January 10, 2026, with monthly cash compensation of US$6,400. The mandate is intended to refine...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Diagnos Advances Global Regulatory Push for AI Eye-Health Platform CARA
Positive
Jan 13, 2026
Diagnos Inc. has outlined significant progress in its regulatory strategy for CARA, its AI platform for early detection of eye-related health issues, across three key jurisdictions. The company has formally submitted CARA for marketing approval to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.